+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators



Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators



Circulation 96(8): 2625-2632



Atrial fibrillation and paroxysmal supraventricular tachycardia are common disorders of the heart rhythm for which antiarrhythmic drug therapy is commonly prescribed. The Atrial Fibrillation Investigation with Bidisomide (AFIB) study was a randomized, placebo-controlled clinical trial designed to accomplish three goals in a single protocol: (1) to determine the efficacy of the antiarrhythmic drug bidisomide in the treatment of these two arrhythmias; (2) to establish the appropriate dose range for bidisomide; and (3) to detect an adverse mortality effect of bidisomide if one were present in patients with atrial fibrillation. In this clinical trial, 1227 patients with atrial fibrillation and 187 with paroxysmal supraventricular tachycardia were randomly assigned to bidisomide (200, 400, or 600 mg BID) or placebo; patient groups with each arrhythmia were analyzed separately. Symptomatic recurrences of atrial fibrillation and paroxysmal supraventricular tachycardia were documented with the use of transtelephonic ECG monitoring. The time to the first symptomatic arrhythmia recurrence was measured in each patient and compared among treatment groups. Among the atrial fibrillation patients, there was no significant difference in the time to first symptomatic recurrence between the placebo group and any of the three bidisomide treatment groups; the hazard ratios (placebo:treatment) were 1.19, 1.03, and 1.14 for bidisomide 200, 400, and 600 mg BID, respectively. Among paroxysmal supraventricular tachycardia patients, there was a similar lack of a significant treatment effect; the hazard ratios were 1.30, 1.93, and 1.59 for bidisomide 200, 400, and 600 mg BID, respectively. In the primary safety analysis of mortality, 3 of 493 patients taking placebo died, compared with 9 of 488 patients taking one of the two higher doses of bidisomide (P>.10). Bidisomide in the doses tested did not have a clinically important antiarrhythmic effect. The AFIB study provided a novel clinical trial design to test antiarrhythmic drugs for both safety and efficacy.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047831088

Download citation: RISBibTeXText

PMID: 9355903


Related references

On a case of supraventricular paroxysmal tachycardia resistant to treatment. Transitory conversion into atrial fibrillation by rapid atrial electric stimulation. Medicina Interna 24(11): 1393-1400, 1972

Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. Journal of the American College of Cardiology 17(2): 297-303, 1991

Circadian variation of paroxysmal atrial fibrillation. PA3 Investigators. Atrial Pacing Peri-ablation for Prevention of Atrial Fibrillation Trial. American Journal of Cardiology 87(6): 794-8 A8, 2001

Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias. Journal of Cardiovascular Electrophysiology 19(2): 172-177, 2008

Atrial late potentials: paroxysmal supraventricular tachycardia versus paroxysmal atrial fibrillation. International Journal of Cardiology 41(2): 147-152, 1993

On the treatment of some states of paroxysmal atrial hyperexcitability (paroxysmal atrial fibrillation, atrial paroxysmal tachycardia with block (?) by means of the contemporaneous administration of digitalis and potassium salts by endovenous route). L' Ospedale Maggiore 48: 561-567, 1960

Sympathetic stimulation affects atrial vulnerability in paroxysmal supraventricular tachycardia patients with atrial fibrillation. International Journal of Cardiology 174(2): 431-432, 2014

Atrial fibrillation prevalence and atrial vulnerability analysis in paroxysmal supraventricular tachycardia patients after radiofrequency ablation. European Review for Medical and Pharmacological Sciences 21(3): 584-589, 2017

Role of atrial electrophysiology and autonomic nervous system in patients with supraventricular tachycardia and paroxysmal atrial fibrillation. Journal of the American College of Cardiology 32(3): 732-738, 1998

Atrial conduction delay predicts atrial fibrillation in paroxysmal supraventricular tachycardia patients after radiofrequency catheter ablation. Ultrasound in Medicine and Biology 40(6): 1133-1137, 2014

Difference in atrial and pulmonary vein orifice dimensions in patients with idiopathic paroxysmal atrial fibrillation and reentrant supraventricular tachycardia. European Heart Journal 22(Abstract Suppl.): 243, 2001

Effect of pulmonary vein isolation on atrial fibrillation recurrence after ablation of paroxysmal supraventricular tachycardia in patients with high dispersion of atrial refractoriness. Journal of Interventional Cardiac Electrophysiology 41(2): 169-175, 2014

Evaluation of the type of cardiac rhythm preceding the onset of atrial fibrillation or supraventricular tachycardia in atrial fibrillation patients. Journal of the American College of Cardiology 35(2 Suppl A): 151A-152A, 2000

Treatment of paroxysmal supraventricular tachycardia and atrial flutter-fibrillation with intravenous verapamil: efficacy and mechanism of action. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 3(1-2): 41-47, 1980

Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. American Journal of Cardiology 74(8): 826-829, 1994